242 related articles for article (PubMed ID: 32509533)
1. Efficacy of bezafibrate in two patients with mitochondrial trifunctional protein deficiency.
Suyama T; Shimura M; Fushimi T; Kuranobu N; Ichimoto K; Matsunaga A; Takayanagi M; Murayama K
Mol Genet Metab Rep; 2020 Sep; 24():100610. PubMed ID: 32509533
[TBL] [Abstract][Full Text] [Related]
2. Management and diagnosis of mitochondrial fatty acid oxidation disorders: focus on very-long-chain acyl-CoA dehydrogenase deficiency.
Yamada K; Taketani T
J Hum Genet; 2019 Feb; 64(2):73-85. PubMed ID: 30401918
[TBL] [Abstract][Full Text] [Related]
3. Open-label clinical trial of bezafibrate treatment in patients with fatty acid oxidation disorders in Japan.
Yamada K; Shiraishi H; Oki E; Ishige M; Fukao T; Hamada Y; Sakai N; Ochi F; Watanabe A; Kawakami S; Kuzume K; Watanabe K; Sameshima K; Nakamagoe K; Tamaoka A; Asahina N; Yokoshiki S; Miyakoshi T; Ono K; Oba K; Isoe T; Hayashi H; Yamaguchi S; Sato N
Mol Genet Metab Rep; 2018 Jun; 15():55-63. PubMed ID: 29552494
[TBL] [Abstract][Full Text] [Related]
4. Medium branched chain fatty acids improve the profile of tricarboxylic acid cycle intermediates in mitochondrial fatty acid β-oxidation deficient cells: A comparative study.
Karunanidhi A; Van't Land C; Rajasundaram D; Grings M; Vockley J; Mohsen AW
J Inherit Metab Dis; 2022 May; 45(3):541-556. PubMed ID: 35076099
[TBL] [Abstract][Full Text] [Related]
5. Metabolic control during exercise with and without medium-chain triglycerides (MCT) in children with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency.
Gillingham MB; Scott B; Elliott D; Harding CO
Mol Genet Metab; 2006; 89(1-2):58-63. PubMed ID: 16876451
[TBL] [Abstract][Full Text] [Related]
6. Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders.
Djouadi F; Aubey F; Schlemmer D; Ruiter JP; Wanders RJ; Strauss AW; Bastin J
Hum Mol Genet; 2005 Sep; 14(18):2695-703. PubMed ID: 16115821
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis, genetic characterization and clinical follow up of mitochondrial fatty acid oxidation disorders in the new era of expanded newborn screening: A single centre experience.
Maguolo A; Rodella G; Dianin A; Nurti R; Monge I; Rigotti E; Cantalupo G; Salviati L; Tucci S; Pellegrini F; Molinaro G; Lupi F; Tonin P; Pasini A; Campostrini N; Ion Popa F; Teofoli F; Vincenzi M; Camilot M; Piacentini G; Bordugo A
Mol Genet Metab Rep; 2020 Sep; 24():100632. PubMed ID: 32793418
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis, Treatment, and Clinical Outcome of Patients with Mitochondrial Trifunctional Protein/Long-Chain 3-Hydroxy Acyl-CoA Dehydrogenase Deficiency.
De Biase I; Viau KS; Liu A; Yuzyuk T; Botto LD; Pasquali M; Longo N
JIMD Rep; 2017; 31():63-71. PubMed ID: 27117294
[TBL] [Abstract][Full Text] [Related]
9. Bezafibrate can be a new treatment option for mitochondrial fatty acid oxidation disorders: evaluation by in vitro probe acylcarnitine assay.
Yamaguchi S; Li H; Purevsuren J; Yamada K; Furui M; Takahashi T; Mushimoto Y; Kobayashi H; Hasegawa Y; Taketani T; Fukao T; Fukuda S
Mol Genet Metab; 2012 Sep; 107(1-2):87-91. PubMed ID: 22841441
[TBL] [Abstract][Full Text] [Related]
10. Clinical and genetic characteristics of patients with fatty acid oxidation disorders identified by newborn screening.
Kang E; Kim YM; Kang M; Heo SH; Kim GH; Choi IH; Choi JH; Yoo HW; Lee BH
BMC Pediatr; 2018 Mar; 18(1):103. PubMed ID: 29519241
[TBL] [Abstract][Full Text] [Related]
11. Open-label clinical trial of bezafibrate treatment in patients with fatty acid oxidation disorders in Japan; 2nd report QOL survey.
Shiraishi H; Yamada K; Oki E; Ishige M; Fukao T; Hamada Y; Sakai N; Ochi F; Watanabe A; Kawakami S; Kuzume K; Watanabe K; Sameshima K; Nakamagoe K; Tamaoka A; Asahina N; Yokoshiki S; Miyakoshi T; Oba K; Isoe T; Hayashi H; Yamaguchi S; Sato N
Mol Genet Metab Rep; 2019 Sep; 20():100496. PubMed ID: 31372341
[TBL] [Abstract][Full Text] [Related]
12. Diversity in the incidence and spectrum of organic acidemias, fatty acid oxidation disorders, and amino acid disorders in Asian countries: Selective screening vs. expanded newborn screening.
Shibata N; Hasegawa Y; Yamada K; Kobayashi H; Purevsuren J; Yang Y; Dung VC; Khanh NN; Verma IC; Bijarnia-Mahay S; Lee DH; Niu DM; Hoffmann GF; Shigematsu Y; Fukao T; Fukuda S; Taketani T; Yamaguchi S
Mol Genet Metab Rep; 2018 Sep; 16():5-10. PubMed ID: 29946514
[TBL] [Abstract][Full Text] [Related]
13. Long-chain fatty acid oxidation during early human development.
Oey NA; den Boer ME; Wijburg FA; Vekemans M; Augé J; Steiner C; Wanders RJ; Waterham HR; Ruiter JP; Attié-Bitach T
Pediatr Res; 2005 Jun; 57(6):755-9. PubMed ID: 15845636
[TBL] [Abstract][Full Text] [Related]
14. Effect of heat stress and bezafibrate on mitochondrial beta-oxidation: comparison between cultured cells from normal and mitochondrial fatty acid oxidation disorder children using in vitro probe acylcarnitine profiling assay.
Li H; Fukuda S; Hasegawa Y; Kobayashi H; Purevsuren J; Mushimoto Y; Yamaguchi S
Brain Dev; 2010 May; 32(5):362-70. PubMed ID: 19589653
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial trifunctional protein deficiency in human cultured fibroblasts: effects of bezafibrate.
Djouadi F; Habarou F; Le Bachelier C; Ferdinandusse S; Schlemmer D; Benoist JF; Boutron A; Andresen BS; Visser G; de Lonlay P; Olpin S; Fukao T; Yamaguchi S; Strauss AW; Wanders RJ; Bastin J
J Inherit Metab Dis; 2016 Jan; 39(1):47-58. PubMed ID: 26109258
[TBL] [Abstract][Full Text] [Related]
16. Bezafibrate activation of PPAR drives disturbances in mitochondrial redox bioenergetics and decreases the viability of cells from patients with VLCAD deficiency.
Lund M; Andersen KG; Heaton R; Hargreaves IP; Gregersen N; Olsen RKJ
Biochim Biophys Acta Mol Basis Dis; 2021 Jun; 1867(6):166100. PubMed ID: 33549744
[TBL] [Abstract][Full Text] [Related]
17. Management and outcome in 75 individuals with long-chain fatty acid oxidation defects: results from a workshop.
Spiekerkoetter U; Lindner M; Santer R; Grotzke M; Baumgartner MR; Boehles H; Das A; Haase C; Hennermann JB; Karall D; de Klerk H; Knerr I; Koch HG; Plecko B; Röschinger W; Schwab KO; Scheible D; Wijburg FA; Zschocke J; Mayatepek E; Wendel U
J Inherit Metab Dis; 2009 Aug; 32(4):488-97. PubMed ID: 19399638
[TBL] [Abstract][Full Text] [Related]
18. Heat stress deteriorates mitochondrial beta-oxidation of long-chain fatty acids in cultured fibroblasts with fatty acid beta-oxidation disorders.
Li H; Fukuda S; Hasegawa Y; Purevsuren J; Kobayashi H; Mushimoto Y; Yamaguchi S
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Jun; 878(20):1669-72. PubMed ID: 20207594
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of mitochondrial long chain fatty acid oxidation and carnitine defects from a single center metabolic genetics clinic.
Ambrose A; Sheehan M; Bahl S; Athey T; Ghai-Jain S; Chan A; Mercimek-Andrews S
Orphanet J Rare Dis; 2022 Sep; 17(1):360. PubMed ID: 36109795
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
